Drug delivery treatment device
First Claim
Patent Images
1. A method of delivering drug into the eye, comprising:
- implanting an elongate member in an eye by inserting the elongate member through the cornea and through the anterior chamber, wherein the elongate member comprises a elongate member having a tubular first end, a second end, and an internal lumen with a first opening at the first end and a second opening adjacent the second end, and wherein the elongate member is implanted in the eye such that the first end is in the anterior chamber, the second end is positioned in communication with a suprachoroidal space of the eye, and at least a portion of the elongate member between the first end and the second end is positioned between the sclera and a ciliary body of the eye, the elongate member adapted to deliver a drug into the eye;
placing a treatment medium onto an outer surface of the eye;
permitting the treatment medium to flow into an anterior chamber of the eye; and
causing the treatment medium to flow into the internal lumen of the elongate member such that the treatment medium flows along the internal lumen of the elongate member into the suprachoroidal space.
4 Assignments
0 Petitions
Accused Products
Abstract
Disclosed are devices and methods for treatment of eye disease. The suprachoroidal space is used as a conduit within which to place a drug delivery device. One such drug delivery device may be a tube, wicking element, bioabsorbable polymer structure, or other configuration of drug delivery substrate. The delivery device may include a port on the proximal end to assist in repeat injection, and may include a reservoir to either collect flow from the aqueous to concentrate it along the length of the device, or act as a repository for injected agent.
-
Citations
11 Claims
-
1. A method of delivering drug into the eye, comprising:
-
implanting an elongate member in an eye by inserting the elongate member through the cornea and through the anterior chamber, wherein the elongate member comprises a elongate member having a tubular first end, a second end, and an internal lumen with a first opening at the first end and a second opening adjacent the second end, and wherein the elongate member is implanted in the eye such that the first end is in the anterior chamber, the second end is positioned in communication with a suprachoroidal space of the eye, and at least a portion of the elongate member between the first end and the second end is positioned between the sclera and a ciliary body of the eye, the elongate member adapted to deliver a drug into the eye; placing a treatment medium onto an outer surface of the eye; permitting the treatment medium to flow into an anterior chamber of the eye; and causing the treatment medium to flow into the internal lumen of the elongate member such that the treatment medium flows along the internal lumen of the elongate member into the suprachoroidal space. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
Specification